CN101755207B - 血红蛋白及血红蛋白衍生物的测定方法、测定试剂盒 - Google Patents
血红蛋白及血红蛋白衍生物的测定方法、测定试剂盒 Download PDFInfo
- Publication number
- CN101755207B CN101755207B CN2008800251182A CN200880025118A CN101755207B CN 101755207 B CN101755207 B CN 101755207B CN 2008800251182 A CN2008800251182 A CN 2008800251182A CN 200880025118 A CN200880025118 A CN 200880025118A CN 101755207 B CN101755207 B CN 101755207B
- Authority
- CN
- China
- Prior art keywords
- haemoglobin
- sex change
- sample
- dervative
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title abstract description 81
- 102000001554 Hemoglobins Human genes 0.000 title abstract description 22
- 108010054147 Hemoglobins Proteins 0.000 title abstract description 22
- 238000005259 measurement Methods 0.000 title abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 303
- 238000004458 analytical method Methods 0.000 claims abstract description 124
- 239000000203 mixture Substances 0.000 claims abstract description 66
- 230000008859 change Effects 0.000 claims description 151
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims description 82
- 108010014663 Glycated Hemoglobin A Proteins 0.000 claims description 82
- 238000012360 testing method Methods 0.000 claims description 81
- 210000004369 blood Anatomy 0.000 claims description 73
- 239000008280 blood Substances 0.000 claims description 73
- 238000003018 immunoassay Methods 0.000 claims description 51
- 238000003556 assay Methods 0.000 claims description 43
- 239000000470 constituent Substances 0.000 claims description 19
- 229910052791 calcium Inorganic materials 0.000 claims description 10
- 229910052749 magnesium Inorganic materials 0.000 claims description 10
- 229910052700 potassium Inorganic materials 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- 150000001455 metallic ions Chemical class 0.000 claims description 9
- 239000000523 sample Substances 0.000 abstract description 94
- 239000012488 sample solution Substances 0.000 abstract description 8
- 230000001900 immune effect Effects 0.000 abstract description 4
- 229910052751 metal Inorganic materials 0.000 abstract description 4
- 239000002184 metal Substances 0.000 abstract description 4
- 150000003839 salts Chemical class 0.000 abstract description 3
- 230000027455 binding Effects 0.000 abstract description 2
- 239000007800 oxidant agent Substances 0.000 abstract description 2
- 239000012503 blood component Substances 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 230000004520 agglutination Effects 0.000 description 172
- 238000006243 chemical reaction Methods 0.000 description 63
- 239000004816 latex Substances 0.000 description 55
- 229920000126 latex Polymers 0.000 description 55
- 239000012895 dilution Substances 0.000 description 45
- 238000010790 dilution Methods 0.000 description 45
- 238000002835 absorbance Methods 0.000 description 40
- 238000002360 preparation method Methods 0.000 description 31
- 239000007788 liquid Substances 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 30
- 238000004519 manufacturing process Methods 0.000 description 29
- -1 alkali metal salt Chemical class 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 24
- 230000004523 agglutinating effect Effects 0.000 description 23
- 239000002245 particle Substances 0.000 description 23
- 239000000839 emulsion Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 230000001070 adhesive effect Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 17
- 239000000853 adhesive Substances 0.000 description 16
- 239000000758 substrate Substances 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 229910052783 alkali metal Inorganic materials 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 13
- 150000001447 alkali salts Chemical class 0.000 description 13
- 239000007900 aqueous suspension Substances 0.000 description 12
- 125000000524 functional group Chemical group 0.000 description 12
- 238000001035 drying Methods 0.000 description 11
- 239000012467 final product Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 11
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000009777 vacuum freeze-drying Methods 0.000 description 10
- VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 9
- 239000008393 encapsulating agent Substances 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 238000011088 calibration curve Methods 0.000 description 8
- 230000003412 degenerative effect Effects 0.000 description 8
- 239000004033 plastic Substances 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 229940032085 sucrose monolaurate Drugs 0.000 description 8
- 239000011734 sodium Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 206010018910 Haemolysis Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000035484 reaction time Effects 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000010241 blood sampling Methods 0.000 description 5
- 239000007767 bonding agent Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000538 analytical sample Substances 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000036632 reaction speed Effects 0.000 description 4
- 238000005057 refrigeration Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 108010044091 Globulins Proteins 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 108700042971 cyanomethemoglobin Proteins 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012943 hotmelt Substances 0.000 description 2
- 238000005213 imbibition Methods 0.000 description 2
- 238000003317 immunochromatography Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000002563 ionic surfactant Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000004879 turbidimetry Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102100031013 Transgelin Human genes 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 229940064734 aminobenzoate Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000004375 physisorption Methods 0.000 description 1
- 239000000088 plastic resin Substances 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
- G01N33/541—Double or second antibody, i.e. precipitating antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/723—Glycosylated haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/726—Devices
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/2525—Stabilizing or preserving
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (15)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP281074/2007 | 2007-10-30 | ||
JP2007281074 | 2007-10-30 | ||
JP284123/2007 | 2007-10-31 | ||
JP2007284123 | 2007-10-31 | ||
PCT/JP2008/003081 WO2009057293A1 (ja) | 2007-10-30 | 2008-10-29 | ヘモグロビン及びヘモグロビン誘導体の測定方法、測定キット |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310288999XA Division CN103353534A (zh) | 2007-10-30 | 2008-10-29 | 血红蛋白及血红蛋白衍生物的测定方法、测定试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101755207A CN101755207A (zh) | 2010-06-23 |
CN101755207B true CN101755207B (zh) | 2013-07-31 |
Family
ID=40590699
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310288999XA Pending CN103353534A (zh) | 2007-10-30 | 2008-10-29 | 血红蛋白及血红蛋白衍生物的测定方法、测定试剂盒 |
CN2008800251182A Active CN101755207B (zh) | 2007-10-30 | 2008-10-29 | 血红蛋白及血红蛋白衍生物的测定方法、测定试剂盒 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310288999XA Pending CN103353534A (zh) | 2007-10-30 | 2008-10-29 | 血红蛋白及血红蛋白衍生物的测定方法、测定试剂盒 |
Country Status (6)
Country | Link |
---|---|
US (2) | US8574913B2 (zh) |
EP (1) | EP2211175B1 (zh) |
JP (2) | JP5465008B2 (zh) |
CN (2) | CN103353534A (zh) |
AT (1) | ATE555386T1 (zh) |
WO (1) | WO2009057293A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2474306A (en) * | 2009-10-12 | 2011-04-13 | Bioproducts Ltd | Methods and device for detecting an analyte |
WO2011126067A1 (ja) * | 2010-04-09 | 2011-10-13 | 東洋紡績株式会社 | 糖化ヘモグロビンの測定方法 |
JP6055236B2 (ja) * | 2011-08-17 | 2016-12-27 | 株式会社三和化学研究所 | 測定方法 |
JP2013238541A (ja) * | 2012-05-16 | 2013-11-28 | Toshiba Corp | 光導波路型測定システムおよび糖化ヘモグロビンの測定方法 |
ES2744633T3 (es) | 2013-03-14 | 2020-02-25 | Instr Laboratory Co | Sensor de hemólisis de sangre entera |
MX2019006914A (es) | 2016-12-16 | 2020-02-07 | Siemens Healthcare Diagnostics Inc | Medicion simultanea de multiples analitos de un ensayo liquido. |
CN108318698A (zh) * | 2017-01-17 | 2018-07-24 | 天津市协和医药科技集团有限公司 | 一种便潜血乳胶增强免疫比浊试剂盒 |
WO2020067396A1 (ja) * | 2018-09-28 | 2020-04-02 | 積水メディカル株式会社 | 糖化ヘモグロビン(%)の測定方法 |
CN110865182B (zh) * | 2019-11-19 | 2023-06-27 | 东莞市东阳光诊断产品有限公司 | 一种阻断剂及其在免疫检测中的应用 |
CN111189904A (zh) * | 2020-01-13 | 2020-05-22 | 深圳华大临床检验中心 | 一种检测生物样本中的蛋白质复合体的方法 |
EP4080218A4 (en) * | 2020-04-20 | 2024-02-28 | Leobio Co., Ltd. | DEVICE AND METHOD FOR MEASURING GLYCATED HEMOGLOBIN |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5258311A (en) * | 1989-07-13 | 1993-11-02 | Miles Inc. | Lithium salts as red blood cell lysing and hemoglobin denaturing reagents |
CN1081765A (zh) * | 1992-03-05 | 1994-02-09 | 曼海姆泊灵格股份公司 | 用于测定血红蛋白衍生物的免疫方法 |
US5288606A (en) * | 1986-06-21 | 1994-02-22 | Boehringer Mannheim Gmbh | Reagent for specific determination of fructosamine |
EP0794435A1 (en) * | 1996-03-07 | 1997-09-10 | Coulter International Corp. | Cyanide-free reagent and method for hemoglobin determination and leukocyte differentiation |
CN1163401A (zh) * | 1996-02-13 | 1997-10-29 | 李占元 | 全自动血球计数仪试剂及配制方法 |
CN1370276A (zh) * | 1999-07-16 | 2002-09-18 | 旭化成株式会社 | 测定物质的方法和用于该方法中的测定试剂 |
EP1873522A1 (en) * | 2005-04-14 | 2008-01-02 | Matsushita Electric Industrial Co., Ltd. | Method for determination of hemoglobin derivative, and reagent composition, assay kit, analysis device and analysis system for use in the method |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4448888A (en) * | 1982-08-24 | 1984-05-15 | Bio-Rad Laboratories, Inc. | Compositions and method for correcting temperature dependence of hemoglobin assays |
US4738932A (en) * | 1985-12-03 | 1988-04-19 | Advanced Polymer Systems, Inc. | Reaginic test for syphilis |
US4968742A (en) | 1987-11-09 | 1990-11-06 | Miles Inc. | Preparation of ligand-polymer conjugate having a controlled number of introduced ligands |
IL94724A (en) | 1989-07-13 | 1994-02-27 | Miles Inc | Decomposition of red blood cells and denaturation of hemoglobin by the use of lithium salts |
US5242832A (en) * | 1990-03-01 | 1993-09-07 | Toa Medical Electronics Co., Ltd. | Reagent for measurement of leukocytes and hemoglobin in blood |
US5314804A (en) * | 1992-03-24 | 1994-05-24 | Serim Research Corporation | Test for Helicobacter pylori |
US5470759A (en) * | 1992-06-10 | 1995-11-28 | Fujirebio, Inc. | Anti-glycated hemoglobin monoclonal antibody and method for measuring glycated hemoglobin |
US6043043A (en) * | 1993-04-02 | 2000-03-28 | Bayer Corporation | Method for the determination of hemoglobin adducts |
JP2677753B2 (ja) * | 1993-07-22 | 1997-11-17 | 株式会社エスアールエル | 凝集イムノアッセイ法 |
JP3879866B2 (ja) * | 1995-04-04 | 2007-02-14 | アボット・ラボラトリーズ | 生物体液中のバンコマイシンの検出および定量化用試薬および方法 |
US5851777A (en) | 1996-02-05 | 1998-12-22 | Dade Behring Inc. | Homogeneous sol-sol assay |
CN1178580A (zh) * | 1996-02-05 | 1998-04-08 | 达德国际有限公司 | 均相溶胶-溶胶测定 |
JP3551678B2 (ja) * | 1996-03-14 | 2004-08-11 | 東ソー株式会社 | ヘモグロビンA1cの測定法及びキット |
EP1239285A1 (en) * | 2001-03-07 | 2002-09-11 | Roche Diagnostics GmbH | Improved homogeneous immunoassay method |
JP2002340895A (ja) | 2001-05-15 | 2002-11-27 | Internatl Reagents Corp | 糖化ヘモグロビンの測定方法 |
DE10162885A1 (de) * | 2001-12-20 | 2003-07-24 | Zahnradfabrik Friedrichshafen | Mehrstufengetriebe |
CN100335903C (zh) | 2002-06-07 | 2007-09-05 | 爱科来株式会社 | 利用使用甲化合物的氧化还原反应的测定方法 |
JP4458802B2 (ja) * | 2003-10-02 | 2010-04-28 | パナソニック株式会社 | 血液中のグルコースの測定方法およびそれに用いるセンサ |
AU2005203321A1 (en) * | 2004-08-03 | 2006-02-23 | Axis-Shield Diagnostics Limited | Assay |
JP2006317401A (ja) * | 2005-05-16 | 2006-11-24 | Matsushita Electric Ind Co Ltd | 免疫凝集阻止反応測定のための免疫反応性凝集剤ならびにそれを用いた測定方法および測定デバイス |
JP4982107B2 (ja) * | 2006-04-28 | 2012-07-25 | アルフレッサファーマ株式会社 | 免疫学的微小粒子の凝集反応を用いる検体の測定方法および測定用キット |
CN101796420B (zh) * | 2007-10-04 | 2013-09-11 | 松下电器产业株式会社 | 分析用仪器和使用该分析用仪器的分析装置及分析方法 |
-
2008
- 2008-10-29 JP JP2009538928A patent/JP5465008B2/ja active Active
- 2008-10-29 CN CN201310288999XA patent/CN103353534A/zh active Pending
- 2008-10-29 CN CN2008800251182A patent/CN101755207B/zh active Active
- 2008-10-29 WO PCT/JP2008/003081 patent/WO2009057293A1/ja active Application Filing
- 2008-10-29 US US12/740,857 patent/US8574913B2/en active Active
- 2008-10-29 AT AT08844941T patent/ATE555386T1/de active
- 2008-10-29 EP EP08844941A patent/EP2211175B1/en active Active
-
2013
- 2013-01-18 JP JP2013006802A patent/JP5738328B2/ja active Active
- 2013-09-12 US US14/025,328 patent/US9151765B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288606A (en) * | 1986-06-21 | 1994-02-22 | Boehringer Mannheim Gmbh | Reagent for specific determination of fructosamine |
US5258311A (en) * | 1989-07-13 | 1993-11-02 | Miles Inc. | Lithium salts as red blood cell lysing and hemoglobin denaturing reagents |
CN1081765A (zh) * | 1992-03-05 | 1994-02-09 | 曼海姆泊灵格股份公司 | 用于测定血红蛋白衍生物的免疫方法 |
CN1163401A (zh) * | 1996-02-13 | 1997-10-29 | 李占元 | 全自动血球计数仪试剂及配制方法 |
EP0794435A1 (en) * | 1996-03-07 | 1997-09-10 | Coulter International Corp. | Cyanide-free reagent and method for hemoglobin determination and leukocyte differentiation |
CN1370276A (zh) * | 1999-07-16 | 2002-09-18 | 旭化成株式会社 | 测定物质的方法和用于该方法中的测定试剂 |
EP1873522A1 (en) * | 2005-04-14 | 2008-01-02 | Matsushita Electric Industrial Co., Ltd. | Method for determination of hemoglobin derivative, and reagent composition, assay kit, analysis device and analysis system for use in the method |
Also Published As
Publication number | Publication date |
---|---|
JP5738328B2 (ja) | 2015-06-24 |
JP5465008B2 (ja) | 2014-04-09 |
EP2211175B1 (en) | 2012-04-25 |
WO2009057293A1 (ja) | 2009-05-07 |
EP2211175A1 (en) | 2010-07-28 |
US20100267048A1 (en) | 2010-10-21 |
EP2211175A4 (en) | 2010-11-10 |
US8574913B2 (en) | 2013-11-05 |
CN103353534A (zh) | 2013-10-16 |
JP2013076713A (ja) | 2013-04-25 |
JPWO2009057293A1 (ja) | 2011-03-10 |
CN101755207A (zh) | 2010-06-23 |
ATE555386T1 (de) | 2012-05-15 |
US9151765B2 (en) | 2015-10-06 |
US20140017814A1 (en) | 2014-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101755207B (zh) | 血红蛋白及血红蛋白衍生物的测定方法、测定试剂盒 | |
CN101160527B (zh) | 血红蛋白衍生物的测定方法、该法中使用的试剂组合物、测定试剂盒、分析设备以及分析*** | |
US8093057B2 (en) | System for quantitative measurement of glycohemoglobin and method for measuring glycohemoglobin | |
CN101796420B (zh) | 分析用仪器和使用该分析用仪器的分析装置及分析方法 | |
JP5348901B2 (ja) | 分析用デバイスを用いた分析方法 | |
EP0590047A1 (en) | Rapid determination of glycated hemoglobin | |
WO1980000455A1 (en) | Colorimetric immunoassay employing a chromoprotein label | |
US20230204575A1 (en) | Methods for determining the concentration of an analyte in the plasma fraction of a sample of whole blood | |
CN105122062A (zh) | 未致敏胶乳试剂的劣化防止方法 | |
WO2014051141A1 (ja) | 無希釈系イムノクロマトグラフ法試薬において希釈試料を測定するための添加物 | |
US20230400457A1 (en) | Modified elisa with hemoglobin correction apparatus and methods thereof | |
JPH0783921A (ja) | 糖化蛋白の測定方法 | |
CROSIGNANI et al. | PROBLEM OF IMMUNOLOGIGAL ASSAY OF HOG | |
TW201819920A (zh) | 免疫學測定方法及測定試劑 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: PANASONIC HEALTHCARE + MEDICAL EQUIPMENT CO., LTD. Free format text: FORMER OWNER: MATSUSHITA ELECTRIC INDUSTRIAL CO, LTD. Effective date: 20140527 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140527 Address after: Ehime Prefecture, Japan Patentee after: Panasonic Healthcare Co., Ltd Address before: Osaka Japan Patentee before: Matsushita Electric Industrial Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: PANASONIC HEALTHCARE HOLDINGS CO., LTD. Free format text: FORMER OWNER: PANASONIC HEALTHCARE + MEDICAL EQUIPMENT CO., LTD. Effective date: 20150402 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150402 Address after: Tokyo, Japan Patentee after: Panasonic's health medical treatment is controlled interest Co., Ltd. Address before: Ehime Prefecture, Japan Patentee before: Panasonic Healthcare Co., Ltd |
|
CP01 | Change in the name or title of a patent holder |
Address after: Tokyo, Japan Patentee after: Pu Hei holding company Address before: Tokyo, Japan Patentee before: Panasonic's health medical treatment is controlled interest Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder |